How do you decide on the duration of endocrine therapy for premenopausal women who receive chemotherapy and AI/ovarian suppression according to TEXT/SOFT?
Answer from: Medical Oncologist at Academic Institution
Women who have a higher than average risk of recurrence (those who receive chemotherapy, younger than 35 Years, stages II or III ....) derive the most benefit from endocrine therapy +ovarian suppression (using monthly GNRH agonists) for 5 years based on TEXT and SOFT in DFS. The joint an...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The SOFT and TEXT trials have provided clear evidence on managing endocrine therapy in the first 5 years; based on these findings, we can consider 5 years as the optimal duration of ovarian function suppression when this treatment is needed. Considering the lack of efficacy and particularly of safet...
Comments
Medical Oncologist at Conway Regional Health System
So if the patient is pre menopausal at the end of ...
So if the patient is pre menopausal at the end of ...
Answer from: Medical Oncologist at Academic Institution
This is a good question. The duration of anti estrogen therapy was not addressed by SOFT/TEXT trials. The recent data presented at SABCS showed the benefit of ovarian suppression in premenopausal women with high risk disease. The ABCsG-16 data presented at SABCS was in postmenopausal women and this ...